Search

Your search keyword '"Delgado Mingorance, I."' showing total 7 results
Start Over Author "Delgado Mingorance, I." Search Limiters Full Text
7 results on '"Delgado Mingorance, I."'

1. 1868P Efficacy and safety of naloxegol in patients with cancer with opioid-induced constipation with laxative-inadequate response: A long-term, real-world study

Author

Beato Zambrano, C., primary, Cobo Dols, M., additional, Cabezón Gutiérrez, L., additional, Chicas-Sett, R., additional, Blancas López-Barajas, M.I., additional, García-Navalón, F.J., additional, Firvida Pérez, J.L., additional, Llorens Torromé, S., additional, Togores Torres, P., additional, Delgado Mingorance, I., additional, Giraldo Marín, A., additional, Librán Oriol, A., additional, Paredes Lario, A., additional, Sánchez Mauriño, P., additional, Higuera Gómez, O., additional, Moreno Muñoz, D., additional, Huerta González, I., additional, Sanz Yagüe, A., additional, and Soler López, B., additional

Published
2020
Full Text
View/download PDF

2. Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results

Author

Salvador, J., primary, Ciruelos, E.M., additional, Jiménez-Rodríguez, B., additional, De La Cruz, L., additional, Villanueva Vázquez, R., additional, De Toro, R., additional, Antón, A., additional, Moreno, F., additional, Álvarez, I., additional, Quiroga, V., additional, de la Haba, J., additional, González-Santiago, S., additional, Díaz, N., additional, Barnadas, A., additional, Cantos, B., additional, Delgado Mingorance, I., additional, Bellet Ezquerra, M., additional, Martín, M., additional, Martínez, N., additional, and Vicente, E., additional

Published
2019
Full Text
View/download PDF

3. Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response

Author

Cobo Dols, M., primary, Beato Zambrano, M.D.C., additional, Cabezón Gutiérrez, L., additional, Chicas Sett, R., additional, Blancas, I., additional, García Navalón, F.J., additional, Firvida Pérez, J.L., additional, Serrano Bermúdez, G., additional, Togores Torres, P., additional, Delgado Mingorance, I., additional, Giraldo Marín, A., additional, Librán Oriol, A., additional, Paredes Lario, A., additional, Sánchez Mauriño, P., additional, Higuera Gomez, O., additional, Moreno Muñoz, D., additional, Jiménez López, A.J., additional, Huerta González, I., additional, Sanz Yagüe, A., additional, and Soler López, B., additional

Published
2019
Full Text
View/download PDF

4. Abstract P6-07-21: High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

Author

Manso Sánchez, L, primary, Moreno Antón, F, additional, Izarzugaza Perón, Y, additional, Delgado Mingorance, I, additional, Borrega García, P, additional, Echarri González, MJ, additional, Martínez Jáñez, N, additional, López González, A, additional, Olier Garate, C, additional, Ballesteros García, A, additional, Chacón López-Muñiz, I, additional, Ciruelos Gil, EM, additional, García Sáenz, JA, additional, and Paz-Ares Rodríguez, L, additional

Published
2017
Full Text
View/download PDF

5. 1821P - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response

Author

Cobo Dols, M., Beato Zambrano, M.D.C., Cabezón Gutiérrez, L., Chicas Sett, R., Blancas, I., García Navalón, F.J., Firvida Pérez, J.L., Serrano Bermúdez, G., Togores Torres, P., Delgado Mingorance, I., Giraldo Marín, A., Librán Oriol, A., Paredes Lario, A., Sánchez Mauriño, P., Higuera Gomez, O., Moreno Muñoz, D., Jiménez López, A.J., Huerta González, I., Sanz Yagüe, A., and Soler López, B.

Published
2019
Full Text
View/download PDF

6. 336P - Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results

Author

Salvador, J., Ciruelos, E.M., Jiménez-Rodríguez, B., De La Cruz, L., Villanueva Vázquez, R., De Toro, R., Antón, A., Moreno, F., Álvarez, I., Quiroga, V., de la Haba, J., González-Santiago, S., Díaz, N., Barnadas, A., Cantos, B., Delgado Mingorance, I., Bellet Ezquerra, M., Martín, M., Martínez, N., and Vicente, E.

Published
2019
Full Text
View/download PDF

7. Observational study to analyze patterns of treatment of breakthrough dyspnea in cancer patients in clinical practice.

Author

Cabezón-Gutiérrez L, Delgado-Mingorance I, Nabal-Vicuña M, Jiménez-López AJ, Cabezón-Álvarez A, and Soler-López B

Subjects
Aged, Cross-Sectional Studies, Dyspnea etiology, Female, Humans, Male, Middle Aged, Spain, Analgesics, Opioid administration & dosage, Dyspnea drug therapy, Neoplasms complications, Oxygen administration & dosage
Abstract

Introduction: Although breakthrough dyspnea is very frequent in cancer patients, there are no precise recommendations for treating it. The main objective of this study was to analyze what treatments are used in clinical practice for the management of breakthrough dyspnea in cancer patients in Spain and the secondary objectives were to describe the characteristics of cancer patients with breakthrough dyspnea and the attributes of the disorder., Methods: Cancer patients over 18 years of age, with breakthrough dyspnea and a Karnofsky performance score of ≥30, who were treated at departments of oncology in institutes across Spain were included in this cross-sectional observational study. The characteristics of breakthrough dyspnea, history of treatment, anthropometric variables, Mahler dyspnea index, Borg scale, Edmonton Symptoms Assessment Scale, and patient satisfaction with current breakthrough dyspnea treatment were assessed., Results: The mean age of the 149 included patients was 66 years (95% confidence interval: 64.3 to 67.9), and 53 were females (35.6%). The mean breakthrough dyspnea intensity was 5.85 (95% confidence interval 5.48 to 6.22, Borg scale). A total of 55.1% of the first-choice treatments consisted of opioids, followed by oxygen (17.3%). A total of 119 patients (79.9%) received monotherapy for breakthrough dyspnea. Patients presenting with basal dyspnea received oxygen in a greater proportion of cases (21.1% vs 7.4%; p = 0.07). Patients with predictable dyspnea received a greater proportion of opioids (70.9% vs 44.4%; p = 0.01)., Conclusions: Opioids constitute first-line therapy for breakthrough dyspnea in routine clinical practice, though the scientific evidence supporting their use is scarce. Further information derived from controlled clinical trials is needed regarding the comparative efficacy of the different treatments in order to justify their use.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results